This Article Full Text Full Text (PDF) Data Supplement All Versions of this Article: 46/2/433    most recent 01.HYP.0000174986.73346.bav1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Graiani, G. Articles by Emanueli, C. Search for Related Content PubMed PubMed Citation Articles by Graiani, G. Articles by Emanueli, C. Pubmed/NCBI databases Gene GEO Profiles HomoloGene UniGene Compound via MeSH Substance via MeSH Medline Plus Health Information Cardiomyopathy Related Collections Other myocardial biology ACE/Angiotension receptors Angiogenesis Apoptosis

(Hypertension. 2005;46:433.)
© 2005 American Heart Association, Inc.

Original Articles

Genetic Deletion of the p66^Shc Adaptor Protein Protects From Angiotensin II–Induced Myocardial Damage

Gallia Graiani; Costanza Lagrasta; Enrica Migliaccio; Frank Spillmann; Marco Meloni; Paolo Madeddu; Federico Quaini; Ines Martin Padura; Luisa Lanfrancone; PierGiuseppe Pelicci; Costanza Emanueli

From the Molecular and Cellular Medicine Laboratory (G.G., M.M., C.E.) and Experimental Medicine and Gene Therapy Section of INBB (F.S., P.M.) Alghero and Osilo, Italy; Pathology (G.G., C.L.) and Internal Medicine (F.Q.), University of Parma, Italy; IFOM-FIRC (E.M.), Milan, Italy; the Bristol Heart Institute (P.M., C.E.), University of Bristol, Bristol, UK; and Hematology-Oncology (I.M.P.) and Experimental Oncology (L.L., P.P.), IEO, Milan, Italy.

Correspondence to Costanza Emanueli, PhD, Division of Experimental Cardiovascular Medicine, Bristol Heart Institute, Bristol Royal Infirmary, University of Bristol, Bristol BS2 8HW, UK. E-mail emanueli{at}yahoo.com

Angiotensin II (Ang II), acting through its G protein–coupled AT₁ receptor (AT₁), contributes to the precocious heart senescence typical of patients with hypertension, atherosclerosis, and diabetes. AT₁ was suggested to transactivate an intracellular signaling controlled by growth factors and their tyrosin-kinase receptors. In cultured vascular smooth muscle cells, this downstream mechanism comprises the p66^Shc adaptor protein, previously recognized to play a role in vascular cell senescence and death. The aim of the present study was 2-fold: (1) to characterize the cardiovascular phenotype of p66^Shc knockout mice (p66^Shc–/–), and (2) to test the novel hypothesis that disrupting the p66^Shc might protect the heart from the damaging action of elevated Ang II levels. Compared with wild-type littermates (p66^Shc+/+), p66^Shc–/– showed similar blood pressure, heart rate, and left ventricular wall thickness. However, cardiomyocyte number was increased in mutant animals, indicating a condition of myocardial hyperplasia. In p66^Shc+/+, infusion of a sub-pressor dose of Ang II (300 nmol/kg body weight [BW] daily for 28 days) caused left ventricular hypertrophy and apoptotic death of cardiomyocytes and endothelial cells. In contrast, p66^Shc–/– were resistant to the proapoptotic/hypertrophic action of Ang II. Consistently, in vitro experiments showed that Ang II causes apoptotic death of cardiomyocytes isolated from p66^Shc+/+ hearts to a greater extent as compared with p66^Shc–/– cardiomyocytes. Our results indicate a fundamental role of p66^Shc in Ang II–mediated myocardial remodeling. In perspective, p66^Shc inhibition may be envisioned as a novel way to prevent the deleterious effects of Ang II on the heart.

Key Words: angiotensin II • cardiomyocytes • endothelial growth factors • apoptosis

This article has been cited by other articles:

				J. Guo, Z. Gertsberg, N. Ozgen, and S. F. Steinberg p66Shc Links {alpha}1-Adrenergic Receptors to a Reactive Oxygen Species-Dependent AKT-FOXO3A Phosphorylation Pathway in Cardiomyocytes Circ. Res., March 13, 2009; 104(5): 660 - 669. [Abstract] [Full Text] [PDF]

				E. M. de Cavanagh, M. Ferder, F. Inserra, and L. Ferder Angiotensin II, mitochondria, cytoskeletal, and extracellular matrix connections: an integrating viewpoint Am J Physiol Heart Circ Physiol, March 1, 2009; 296(3): H550 - H558. [Abstract] [Full Text] [PDF]

				A. Malhotra, H. Vashistha, V. S. Yadav, M. G. Dube, S. P. Kalra, M. Abdellatif, and L. G. Meggs Inhibition of p66ShcA redox activity in cardiac muscle cells attenuates hyperglycemia-induced oxidative stress and apoptosis Am J Physiol Heart Circ Physiol, February 1, 2009; 296(2): H380 - H388. [Abstract] [Full Text] [PDF]

				C.-S. Kim, S.-B. Jung, A. Naqvi, T. A. Hoffman, J. DeRicco, T. Yamamori, M. P. Cole, B.-H. Jeon, and K. Irani P53 Impairs Endothelium-Dependent Vasomotor Function Through Transcriptional Upregulation of P66shc Circ. Res., December 5, 2008; 103(12): 1441 - 1450. [Abstract] [Full Text] [PDF]

				D.H. Betts and P. Madan Permanent embryo arrest: molecular and cellular concepts Mol. Hum. Reprod., August 1, 2008; 14(8): 445 - 453. [Abstract] [Full Text] [PDF]

				F. Cosentino, P. Francia, G. G. Camici, P. G. Pelicci, M. Volpe, and T. F. Luscher Final Common Molecular Pathways of Aging and Cardiovascular Disease: Role of the p66Shc Protein Arterioscler Thromb Vasc Biol, April 1, 2008; 28(4): 622 - 628. [Abstract] [Full Text] [PDF]

				G. Zaccagnini, F. Martelli, A. Magenta, C. Cencioni, P. Fasanaro, C. Nicoletti, P. Biglioli, P. G. Pelicci, and M. C. Capogrossi p66ShcA and Oxidative Stress Modulate Myogenic Differentiation and Skeletal Muscle Regeneration after Hind Limb Ischemia J. Biol. Chem., October 26, 2007; 282(43): 31453 - 31459. [Abstract] [Full Text] [PDF]

				N. Basso, R. Cini, A. Pietrelli, L. Ferder, N. A. Terragno, and F. Inserra Protective effect of long-term angiotensin II inhibition Am J Physiol Heart Circ Physiol, September 1, 2007; 293(3): H1351 - H1358. [Abstract] [Full Text] [PDF]

				W. M Maharsy, L. N Kadi, N. G Issa, K. M Bitar, A. H Der-Boghossian, R. Abrahamian, and A. B Bikhazi Cross-talk related to insulin and angiotensin II binding on myocardial remodelling in diabetic rat hearts Journal of Renin-Angiotensin-Aldosterone System, June 1, 2007; 8(2): 59 - 65. [Abstract] [PDF]

				J. Chintapalli, S. Yang, D. Opawumi, S. R. Goyal, N. Shamsuddin, A. Malhotra, K. Reiss, and L. G. Meggs Inhibition of wild-type p66ShcA in mesangial cells prevents glycooxidant-dependent FOXO3a regulation and promotes the survival phenotype Am J Physiol Renal Physiol, February 1, 2007; 292(2): F523 - F530. [Abstract] [Full Text] [PDF]

				M. Obreztchikova, H. Elouardighi, M. Ho, B. A. Wilson, Z. Gertsberg, and S. F. Steinberg Distinct Signaling Functions for Shc Isoforms in the Heart J. Biol. Chem., July 21, 2006; 281(29): 20197 - 20204. [Abstract] [Full Text] [PDF]

				E. Messina and A. Giacomello Diabetic Cardiomyopathy: A "Cardiac Stem Cell Disease" Involving p66Shc, an Attractive Novel Molecular Target for Heart Failure Therapy Circ. Res., July 7, 2006; 99(1): 1 - 2. [Full Text] [PDF]

				G. W. Booz Growing Old, Angiotensin II, Cardiac Hypertrophy, and Death: Making the Connection With p66Shc Hypertension, August 1, 2005; 46(2): 259 - 260. [Full Text] [PDF]